pindolol (visken) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. The partial beta-adrenergic agonistic activity of pindolol in the heart appears to be completely restricted to the sinoatrial pacemaker. In standard pharmacologic tests in man and animals, Pindolol attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. In addition to beta-adrenergic activity pindolol demonstrates mixed agonist-antagonist activity at central 5-HT receptors. Although in accordance with the hypothesis that pindolol increases the antidepressant effects of selective serotonin reuptake inhibitors by antagonism of 5-HT at inhibitory 5-HT1A autoreceptors, pindolol possesses partial agonist activity at 5-HT1A receptors. Pindolol tablets are indicated in the management of hypertension.   NCATS

Chemistry

  • SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
  • InChIKey: JZQKKSLKJUAGIC-UHFFFAOYSA-N
  • Mol. Mass: 248.3208
  • ALogP: 1.91
  • ChEMBL Molecule:
    pindolol  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.1619 - $0.3245

United States

$0.9013 - $1.2263
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( pindolol (visken), hydrochlorothiazide (esidrix) )

Alternative names

1-(1h-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol | 1-(1h-indol-4-yloxy)-3-(isopropylamino)propan-2-ol | 1-(1h-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol | 4-(2-hydroxy-3-isopropylaminopropoxy)-indole | betadren | betapindol | dl-pindolol | durapindol | lb-46 | pinbetol | pindolol | pindololum | prinodolol | visken

Organizations (33)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Hypertension (approved 1982)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Amphetamine-Related Disorders (Phase 1)

Cachexia (Phase 1)

Depression (Phase 4)

Depressive Disorder (Phase 2/Phase 3)

Depressive Disorder, Major (Phase 2)

Healthy Volunteers (Phase 1)

Mood Disorders (Phase 1)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue